ArticleQuantitative imaging in medicine and surgery2024
Prediction of histologic grade of hepatocellular carcinoma using dual-layer spectral-detector computed tomography (CT): comparison of two region of interest plotting methods.
Article in Quantitative imaging in medicine and surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Dual-layer spectral detector computed tomography of peritumoral fat for preoperative prediction of tumor budding in colorectal adenocarcinoma.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Early recurrence of hepatocellular carcinoma after hepatectomy: predictive role of whole-tumor iodine density histogram features and resection margin distance.Abdominal radiology (New York) · 2026Article
- Whole-lesion iodine map histogram analysis combined with focal ROI iodine concentrations for preoperative prediction of cytokeratin 19-positive hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Multiparametric dual-energy computed tomography radiomics for predicting microvascular invasion in hepatocellular carcinoma.BMC medical imaging · 2025Article
- New Insights into the Diagnosis and Treatment of Hepatocellular Carcinoma.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Multi-parameter imaging technology, which is based on substance separation, helps to predict the pathological grade of tumors. When using dual-layer spectral-detector computed tomography (DLCT) to quantify tumor properties, different methods of placing regions of interest (ROIs) directly impact the measurement of parameters, thus affecting the clinical diagnosis of lesions. Consequently, in this study, we aimed to compare the performance of 2 different ROI plotting methods on DLCT in differentiating the histologic grade of hepatocellular carcinoma (HCC). Methods: This retrospective study included 48 consecutive patients with pathologically confirmed HCC, who underwent DLCT from May 2022 to March 2023. The attenuation value of conventional computed tomography (CT), electron density relative to water (EDW), normalized effective atomic number (NZeff), and normalized iodine density (NID) were measured by 2 radiologists using the conventional planar sketching (PS) method and the volumetric analysis method, respectively. The differences in parameters between the arterial phase (AP) and venous phase (VP) were calculated for each parameter (∆CT, ∆EDW, ∆NZeff, ∆NID). We used 2-sample Results: The mean values for the spectral quantitative parameters (CT Conclusions: The spectral parameters of DLCT provide a novel quantitative method for evaluating histological differentiation in patients with HCC, which is worthy of clinical recommendation. Different ROI plotting methods significantly impact the measurement of spectral parameters. Therefore, the whole tumor region should be covered in the parameter measurement of HCC lesions as much as feasible, which is more helpful in predicting the histological grading of tumors before treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.